Apellis Pharmaceuticals (APLS) has disclosed a new risk, in the Sales & Marketing category. Apellis Pharmaceuticals is facing a significant ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.

AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

Overall, by delivering system-wide insights into fluid behaviors, advanced imaging techniques are vital for next-generation ...

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that the company has entered into a definitive agreement with Solventum (NYSE: SOLV) ...

Thermo Fisher Scientific said Tuesday it is buying Solventum’s purification and filtration business, confirming an earlier ...

RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given ...